Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-618-5 | CAS number: 85-60-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Substance is not mutagenic in the presence and absence of metabolic activation.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 14 May 2012 to 24 July 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study performed in accordance with OECD & EU test guidelines in compliance with GLP.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.17 (Mutagenicity - In Vitro Mammalian Cell Gene Mutation Test)
- GLP compliance:
- yes
- Type of assay:
- mammalian cell gene mutation assay
- Target gene:
- thymidine-kinase locus (TK-locus).
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- Test System: L5178Y/TK+/--3.7.2C mouse lymphoma cells.
Rationale: Recommended test system in international guidelines (e.g. OECD, EC) and literature.
Source: American Type Culture Collection, (ATCC, Manassas, USA) (2001).
Stock cultures of the cells were stored in liquid nitrogen (-196°C). The cultures were checked for mycoplasma contamination. Cell density was preferably kept below 1 x 106 cells/ml. - Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- rat liver microsomal enzymes (S9-mix)
- Test concentrations with justification for top dose:
- Based on the results of the dose range finding test, the following dose range was selected for the first mutagenicity test:
Without S9-mix: 0.03, 0.1, 0.3, 1, 3, 10, 15, 20, 25, 30 and 35 μg/ml exposure medium.
With 8% (v/v) S9-mix: 0.3, 1, 3, 10, 20, 30, 50, 65, 85, 100 and 125 μg/ml exposure medium.
The dose levels selected to measure mutation frequencies at the TK-locus were:
Without S9-mix: 0.03, 0.1, 0.3, 1, 3, 10 and 15 μg/ml exposure medium.
With 8% (v/v) S9-mix: 0.3, 1, 3, 10, 20, 30 and 50 μg/ml exposure medium.
Based on the results of the dose range finding test and experiment 1, the following dose levels were selected for mutagenicity testing.
Without S9-mix: 0.03, 0.1, 0.3, 1, 3, 6.6, 10, 12.5, 15, 17.5, 20 and 22.5 μg/ml exposure medium.
With 12% (v/v) S9-mix: 1, 3, 10, 20, 30, 50, 60, 65, 70 and 75 μg/ml exposure medium.
The dose levels selected to measure mutation frequencies at the TK-locus were:
Without S9-mix: 0.3, 1, 3, 6.6, 10, 12.5, 15 and 17.5 μg/ml exposure medium.
With S9-mix: 1, 3, 10, 30, 50, 60, 65 and 70 μg/ml exposure medium. - Vehicle / solvent:
- The test substance was dissolved in ethanol (Merck, Darmstadt, Germany). 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol concentrations were used within 1 hour after preparation. The final concentration of the solvent in the exposure medium was 0.4% (v/v).
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- ethanol
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- methylmethanesulfonate
- Details on test system and experimental conditions:
- Negative control: The solvent for the test article, i.e. ethanol.
Positive controls
Without metabolic activation (-S9-mix): Methyl methane sulfonate (MMS); CAS no. 66-27-3 (purity 98%, Sigma, Zwijndrecht, The Netherlands). MMS was used as a direct acting mutagen at a concentration of 15 and 5 μg/ml for a 3 and 24 hours treatment period, respectively. MMS was dissolved in dimethyl sulfoxide (Merck Darmstadt, Germany). The stock solutions of MMS were prepared immediately before use.
With metabolic activation (+S9-mix): Cyclophosphamide (CP); CAS no. 50-18-0 (purity 100%, Endoxan, Asta-Werke, Germany). CP was used as an indirect acting mutagen, requiring metabolic activation, at a final concentration of 7.5 and 10 μg/ml in the first and second experiment, respectively. CP was dissolved in Hanks’ balanced salt solution (HBSS) (Invitrogen Corporation, Breda, The Netherlands) without calcium and magnesium.
The stock solutions of CP were stored in aliquots at ≤-15C in the dark and one sample was thawed immediately before use.
Cell culture
Horse serum: Horse serum (Invitrogen Corporation) was inactivated by incubation at 56°C for at least 30 minutes.
Basic medium: RPMI 1640 Hepes buffered medium (Dutch modification) (Invitrogen Corporation) containing penicillin/streptomycin (50 U/ml and 50 μg/ml, respectively) (Invitrogen), 1 mM sodium pyruvate (Sigma) and 2 mM L-glutamin (Invitrogen Corporation).
Growth medium: Basic medium, supplemented with 10% (v/v) heat-inactivated horse serum (=R10 medium).
Exposure medium
For 3 hour exposure: Cells were exposed to the test substance in basic medium supplemented with 5% (v/v) heat-inactivated horse serum (R5-medium).
For 24 hour exposure: Cells were exposed to the test substance in basic medium supplemented with 10% (v/v) heat-inactivated horse serum (R10-medium).
Selective medium: Selective medium consisted of basic medium supplemented with 20% (v/v) heat-inactivated horse serum (total amount of serum = 20%, R20) and 5 μg/ml trifluorothymidine (TFT) (Sigma).
Non-selective medium: Non-selective medium consisted of basic medium supplemented with 20% (v/v) heat-inactivated horse serum (total amount of serum = 20%, R20).
Environmental conditions: All incubations were carried out in a controlled environment in the dark, in which optimal conditions were a humid atmosphere of 80 – 100% (actual range 36 – 97%), containing 5.0 ± 0.5% CO2 in air, at a temperature of 37.0 ± 1.0°C (actual range 35.7 – 37.6°C). Temperature and humidity were continuously monitored throughout the experiment. The CO2 percentage was monitored once on each working day. Temporary deviations from the temperature (in the range of 35.7 - 36.0°C), humidity (with a maximum of 25%) and CO2 percentage (with a maximum of 1%) occurred that were caused by opening and closing of the incubator door, but the time of these deviations did not exceed 4 hours. Based on laboratory historical data these deviations are considered not to affect the study integrity. The temporary deviations from the humidity during the subculturing period are explained in protocol deviation 1.
Metabolic activation system
Preparation of S9-fraction: In the dose range finding test and the first mutation experiment, rat liver microsomal enzymes were routinely prepared in the house and adult male Wistar rats were used, which were obtained from Charles River, Sulzfeld, Germany.
The animals were housed at WIL Research Europe in a special room under standard laboratory conditions, as described in the Standard Operating Procedures. The rats were orally dosed at three consecutive days with a suspension of phenobarbital (Bufa B.V., IJsselstein, The Netherlands) (80
mg/kg body weight) and ß-naphthoflavone (Sigma Aldrich Chemie) (100 mg/kg body weight) in corn oil (Roth, Karlsruhe, Germany) (they were denied access to food for 3 to 4 hours preceding each dosing). One day after the final exposure (24 h), the rats were sedated using oxygen/carbon dioxide and then killed by decapitation. The rats received a limited quantity of food during the night before sacrifice. The livers of the rats were removed aseptically, and washed in cold (0°C) sterile 0.1 M sodium phosphate buffer (pH 7.4, Merck) containing 0.1 mM Na2-EDTA (Merck). Subsequently the livers were minced in a blender and homogenized in 3 volumes of phosphate buffer with a Potter homogenizer. The homogenate was centrifuged for 15 min at 9000 g. The supernatant (S9-fraction) was transferred into sterile ampules, which were stored in liquid nitrogen (-196°C) for a maximum of 1 year.
In the second mutation experiment, rat liver microsomal enzymes (S9 homogenate) were obtained from Trinova Biochem GmbH, Giessen, Germany and was prepared from male Sprague Dawley rats that have been dosed orally with a suspension of phenobarbital (80 mg/kg body weight) and ß-naphthoflavone (100 mg/kg).
Preparation of S9-mix: S9-mix was prepared immediately before use and kept on ice. S9-mix contained per ml: 1.63 mg MgCl2.6H2O (Merck); 2.46 mg KCl (Merck); 1.7 mg glucose-6-phosphate (Roche Diagnostics, Mannheim, Germany); 3.4 mg NADP (Randox Laboratories Ltd., Crumlin, United Kingdom) and 4 μmol HEPES (Invitrogen).The above solution was filter (0.22 μm)-sterilized. To 0.5 ml S9-mix components 0.5 ml S9-fraction was added (50% (v/v) S9-fraction) to complete the S9-mix in the first experiment and to 0.3 ml S9-mix components 0.7 ml S9-fraction was added (70% (v/v) S9-fraction) to complete the S9-mix in the second experiment.
Metabolic activation was achieved by adding 1.3 ml S9-mix to a total of 8 ml, the concentration of the S9-fraction in the exposure medium was 8% (v/v) in the dose range finding test and the first experiment and 12% (v/v) in the second experiment. The S9-batches used were 12-4, 12-5, 2836, 2930 and 2879.
Study design
Cleansing: Prior to dose range finding and mutagenicity testing, the mouse lymphoma cells were grown for 1 day in R10 medium containing 10-4 M hypoxanthine (Sigma), 2 x 10-7 M aminopterine (Fluka Chemie AG, Buchs, Switzerland) and 1.6 x 10-5 M thymidine (Merck) (HAT-medium) to reduce the amount of spontaneous mutants, followed by a recovery period of 2 days on R10 medium containing hypoxanthine and thymidine only. After this period cells were returned to R10 medium for at least 1 day before starting the experiment.
Dose range finding test: In order to select appropriate dose levels for mutagenicity testing, cytotoxicity data were obtained by treating 8 x 106 cells (106 cells/ml for 3 hours treatment) or 5 x 106 cells (1.25 x 105 cells/ml for 24 hours treatment) with a number of test substance concentrations increasing with approximately half log steps. The cell cultures for the 3 hours treatment were placed in sterile 30 ml centrifuge tubes, and incubated in a shaking incubator at 37.0 ± 1.0°C and 145 spm. The cell cultures for the 24 hours treatment were placed in sterile 75 cm2 culture flasks at 37.0 ± 1.0°C. 6,6’-di-tert-butyl-4,4’- butylidenedi-m-cresol was tested in the absence and presence of 8% (v/v) S9-fraction.
Since 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol was poorly soluble in culture medium, the highest tested concentration was 333 μg/ml exposure medium.
Cell cultures were exposed to 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol in exposure medium for 3 hours in the presence of S9-mix and for 3 and 24 hours in the absence of S9-mix. After exposure, the cells were separated from treatment solutions by 2 centrifugation steps (216 g, 8 min) each followed by removal of the supernatant. The first centrifugation step was followed by removal of the supernatant and resuspension of the cells in Hanks’ balanced salt solution and after the final centrifugation step the cells were resuspended in R10 medium. The cells in the final suspension were counted with the coulter particle counter.
For determination of the cytotoxicity, the surviving cells of the 3 hours treatment were subcultured twice. After 24 hours of subculturing, the cells were counted and subcultured again for another 24 hours, after that the cells were counted. The surviving cells of the 24 hours treatment were subcultured once. After 24 hours of subculturing, the cells were counted. If less than 1.25 x 105 cells/ml were counted no subculture was performed.
The suspension growth expressed as the reduction in cell growth after approximately 24 and 48 hours or only 24 hours cell growth, compared to the cell growth of the solvent control, was used to determine an appropriate dose range for the mutagenicity tests.
Mutagenicity test: 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol was tested both in the absence and presence of S9-mix in two independent experiments. Per culture 8 x 106 cells (106 cells/ml for 3 hours treatment) or 5 x 106 cells (1.25 x 105 cells/ml for 24 hours treatment) were used. The cell cultures for the 3 hours treatment were placed in sterile 30 ml centrifuge tubes, and incubated in a shaking incubator at 37.0 ± 1.0°C and 145 spm. The cell cultures for the 24 hours treatment were placed in sterile 75 cm2 culture flasks at 37.0 ± 1.0°C. Solvent and positive controls were included and the solvent control was tested in duplicate.
In the first experiment, cell cultures were exposed for 3 hours to 6,6’-di-tert-butyl-4,4’-butylidenedi-mcresol in exposure medium in the absence and presence of S9-mix. In the second experiment, cell cultures were exposed to 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol in exposure medium for 24 hours in the absence of S9-mix and for 3 hours in the presence of S9-mix.
After exposure, the cells were separated from treatment solutions by 2 centrifugation steps (216 g, 8 min) each followed by removal of the supernatant. The first centrifugation step was followed by removal of the supernatant and resuspension of the cells in Hanks’ balanced salt solution and after the final centrifugation step the cells were resuspended in R10 medium. The cells in the final suspension were counted with the coulter particle counter.
Expression period: For expression of the mutant phenotype, the remaining cells were cultured for 2 days after the treatment period. During this culture period at least 4 x 106 cells (if possible) were subcultured every day in order to maintain log phase growth. Two days after the end of the treatment with the test substance the cells were plated for determination of the cloning efficiency (CEday2) and the mutation frequency (MF).
Determination of the mutation frequency: Seven or eight doses of the test substance were selected for the mutation assay in the first and second experiment, respectively (see protocol deviation 2).
For determination of the CEday2 the cell suspensions were diluted and seeded in wells of a 96-well dish. 1 cell was added per well (2 x 96-well microtiter plates/concentration) in non selective medium. At the mid dose of 1 μg/ml in the first experiment (presence of S9-mix) a total number of 184 wells was used for determination of the CEday2 (see protocol deviation 3).
For determination of the MF a total number of 9.6 x 105 cells/concentration were plated in five 96-well microtiter plates, each well containing 2000 cells in selective medium (TFT-selection), with the exception of the positive control groups (MMS and CP) where a total number of 9.6 x 105 cells/concentration were plated in ten 96-well microtiter plates, each well containing 1000 cells in selective medium (TFT-selection). The microtiter plates for CEday2 and MF were incubated for 11 or 12 days. After that, the plates for the TFT-selection were stained for 2 hours, by adding 0.5 mg/ml 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Sigma) to each well. The plates for the CE day2 and MF were scored with the naked eye or with the microscope. - Evaluation criteria:
- A test substance is considered positive (mutagenic) in the mutation assay if it induces a MF of more than MF(controls) + 126 in a dose-dependent manner. An observed increase should be biologically relevant and will be compared with the historical control data range.
A test substance is considered equivocal (questionable) in the mutation assay if no clear conclusion for positive or negative result can be made after an additional confirmation study.
A test substance is considered negative (not mutagenic) in the mutation assay if:
a) None of the tested concentrations reaches a mutation frequency of MF(controls) + 126.
b) The results are confirmed in an independently repeated test. - Statistics:
- The global evaluation factor (GEF) has been defined by the IWGT as the mean of the negative/solvent MF distribution plus one standard deviation. For the micro well version of the assay the GEF is 126
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- Solubility: 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol precipitated in the exposure medium at concentrations of 100 μg/ml and above. 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol was tested beyond the limit of the solubility to obtain adequate cytotoxicity data, the concentration used as the highest test substance concentration for the dose range finding test was 333 μg/ml.
Dose range finding test: In the dose range finding test, L5178Y mouse lymphoma cells were treated with a test substance concentration range of 3 to 333 μg/ml in the absence of S9-mix with a 3 and 24 hour treatment period and in the presence of S9-mix with a 3 hour treatment period.
In the absence of S9-mix, the relative suspension growth was 12% at the test substance concentration of 33 μg/ml compared to the relative suspension growth of the solvent control. Hardly any cell survival was observed at test substance concentrations of 100 μg/ml and above.
In the presence of S9-mix, the relative suspension growth was 10% at the test substance concentration of 333 μg/ml compared to the relative suspension growth of the solvent control.
In the absence of S9-mix, the relative suspension growth was 63% at the test substance concentration of 10 μg/ml compared to the relative suspension growth of the solvent control. Hardly any cell survival was observed at test substance concentrations of 33 μg/ml and above.
Mutation experiment: Further investigation showed that at a concentration of 35 μg/ml 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol already precipitated in the exposure medium. 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol was tested beyond the limit of the solubility to obtain adequate mutagenicity data.
First mutagenicity test: Based on the results of the dose range finding test, the following dose range was selected for the first mutagenicity test:
Without S9-mix: 0.03, 0.1, 0.3, 1, 3, 10, 15, 20, 25, 30 and 35 μg/ml exposure medium.
With 8% (v/v) S9-mix: 0.3, 1, 3, 10, 20, 30, 50, 65, 85, 100 and 125 μg/ml exposure medium.
Evaluation of toxicity: In the absence of S9-mix, the dose levels of 20 to 35 μg/ml were not used for mutation frequency measurement, since these dose levels were too toxic for further testing. In the presence of S9-mix, the dose levels of 65 to 125 μg/ml were not used for mutation frequency measurement, since these dose levels were too toxic for further testing.
The dose levels selected to measure mutation frequencies at the TK-locus were:
Without S9-mix: 0.03, 0.1, 0.3, 1, 3, 10 and 15 μg/ml exposure medium.
With 8% (v/v) S9-mix: 0.3, 1, 3, 10, 20, 30 and 50 μg/ml exposure medium.
In the absence of S9-mix, the relative total growth of the highest test substance concentration was reduced by 74% compared to the total growth of the solvent controls (see protocol deviation 2).
In the presence of S9-mix, the relative total growth of the highest test substance concentration was reduced by 46% compared to the total growth of the solvent controls (see protocol deviation 2).
Evaluation of the mutagenicity: No significant increase in the mutation frequency at the TK locus was observed after treatment with 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol either in the absence or in the presence of S9-mix. The numbers of small and large colonies in the 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol treated cultures were comparable to the numbers of small and large colonies of the solvent controls.
Second mutagenicity test: To obtain more information about the possible mutagenicity of 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol, a second mutation experiment was performed in the absence of S9-mix with a 24 hour treatment period and in the presence of 12% (v/v) S9-mix with a 3 hour treatment period. Based on the results of the dose range finding test and experiment 1, the following dose levels were selected for mutagenicity testing.
Without S9-mix: 0.03, 0.1, 0.3, 1, 3, 6.6, 10, 12.5, 15, 17.5, 20 and 22.5 μg/ml exposure medium.
With 12% (v/v) S9-mix: 1, 3, 10, 20, 30, 50, 60, 65, 70 and 75 μg/ml exposure medium.
Evaluation of toxicity: In the absence of S9-mix, the dose levels of 0.03 to 10 μg/ml showed no cytotoxicity. Therefore, the dose levels of 0.03 and 0.1 μg/ml were not regarded relevant for mutation frequency measurement. The dose levels of 20 to 22.5 μg/ml were not used for mutation frequency measurement, since these dose levels were too toxic for further testing.
In the presence of S9-mix, the dose levels of 1 to 20 μg/ml showed no cytotoxicity. Therefore, the dose level of 20 μg/ml was not regarded relevant for mutation frequency measurement. The dose level of 75 μg/ml was not used for mutation frequency measurement, since this dose level was too toxic for further testing.
The dose levels selected to measure mutation frequencies at the TK-locus were:
Without S9-mix: 0.3, 1, 3, 6.6, 10, 12.5, 15 and 17.5 μg/ml exposure medium.
With S9-mix: 1, 3, 10, 30, 50, 60, 65 and 70 μg/ml exposure medium.
In the absence of S9-mix, the relative total growth of the highest test substance was reduced by 94% compared to the total growth of the solvent controls (see protocol deviation 4).
In the presence of S9-mix, the relative total growth of the highest test substance concentration was reduced by 83% compared to the total growth of the solvent controls.
Evaluation of mutagenicity: No significant increase in the mutation frequency at the TK locus was observed after treatment with 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol either in the absence or in the presence of S9-mix. The numbers of small and large colonies in the 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol treated cultures were comparable to the numbers of small and large colonies of the solvent controls. - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):
negative with and without metabolic activation
6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol is not mutagenic in the TK mutation test system under the experimental conditions described in this report. - Executive summary:
Evaluation of the mutagenic activity of 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol in an in vitro mammalian cell gene mutation test with L5178Y mouse lymphoma cells (with independent repeat).
This report describes the effects of 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol on the induction of forward mutations at the thymidine-kinase locus (TK-locus) in L5178Y mouse lymphoma cells. The test was performed in two independent experiments in the absence and presence of S9-mix (rat liver S9-mix induced by a combination of phenobarbital and ß-naphthoflavone).
The study procedures described in this report were based on the most recent OECD and EC guidelines. The study was performed in accordance with the Principles of Good Laboratory Practice (GLP).
Batch W4B9F0001 of 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol was a white powder with a purity of 99.4%. The test substance was dissolved in ethanol.
In the first experiment, 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol was tested up to concentrations of 15 and 50 μg/ml in the absence and presence of 8% (v/v) S9-mix, respectively. The incubation time was 3 hours. 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol was tested up to cytotoxic levels of 74 and 46% in the absence and presence of S9-mix, respectively. 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol precipitated in the culture medium at dose levels of 35 μg/ml and above.
In the second experiment, 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol was tested up to concentrations of 17.5 and 70 μg/ml in the absence and presence of 12% (v/v) S9-mix, respectively. The incubation times were 24 hours in the absence of S9-mix and 3 hours for incubations in the presence of S9-mix. The test substance tested up to cytotoxic levels of 94 and 83% in the absence and presence of S9-mix, respectively. 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol precipitated in the culture medium at dose levels of 50 μg/ml and above.
The spontaneous mutation frequencies in the solvent-treated control cultures were between the minimum and maximum value of the historical control data range and within the acceptability criteria of this assay. Except the response of one of the solvent control cultures in the second experiment in the absence of S9-mix. However since this response was just above the upper limit of the range and clear negative results were obtained, the validity of the test was considered to be not affected.
Mutation frequencies in cultures treated with positive control chemicals were increased by 12- and 11-fold for MMS in the absence of S9-mix, and by 12- and 10-fold for CP in the presence of S9-mix. It was therefore concluded that the test conditions, both in the absence and presence of S9-mix, were appropriate and that the metabolic activation system (S9-mix) functioned properly.
In the absence of S9-mix, 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol did not induce a significant increase in the mutation frequency in the first experiment. This result was confirmed in an independent repeat experiment with modifications in the duration of treatment time.
In the presence of S9-mix, 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol did not induce a significant increase in the mutation frequency in the first experiment. This result was confirmed in an independent repeat experiment with modifications in the concentration of the S9 for metabolic activation.
It is concluded that 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol is not mutagenic in the mouse lymphoma L5178Y test system under the experimental conditions described in this report.
Reference
Table 1: Experiment 1; Cytotoxic and mutagenic response of 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol in the mouse lymphoma L5178Y test system
Dose |
RSG |
CE day2 |
RS day2 |
RTG |
Mutation frequency per 106survivors |
||
(μg/ml) |
(%) |
(%) |
(%) |
(%) |
Total |
( small |
Large ) |
Without metabolic activation |
|||||||
3 hours treatment |
|||||||
SC1 |
|
120 |
|
|
64 |
( 24 |
37 ) |
|
100 |
|
100 |
100 |
|
|
|
SC2 |
|
89 |
|
|
85 |
( 26 |
55 ) |
0.03 |
91 |
105 |
101 |
92 |
69 |
( 24 |
42 ) |
0.1 |
103 |
97 |
93 |
96 |
79 |
( 18 |
59 ) |
0.3 |
92 |
97 |
93 |
85 |
70 |
( 33 |
35 ) |
1 |
97 |
99 |
95 |
93 |
76 |
( 36 |
37 ) |
3 |
106 |
101 |
97 |
102 |
69 |
( 22 |
44 ) |
10 |
91 |
120 |
115 |
105 |
64 |
( 21 |
40 ) |
15 |
29 |
93 |
89 |
26 |
66 |
( 25 |
38 ) |
MMS |
59 |
53 |
51 |
30 |
887 |
( 332 |
453 ) |
With 8% (v/v) metabolic activation |
|||||||
3 hours treatment |
|||||||
SC1 |
|
77 |
|
|
107 |
( 25 |
79 ) |
|
100 |
|
100 |
100 |
|
|
|
SC2 |
|
84 |
|
|
90 |
( 11 |
77 ) |
0.3 |
93 |
113 |
141 |
131 |
87 |
( 26 |
58 ) |
1 |
95 |
94 |
117 |
111 |
96 |
( 38 |
54 ) |
3 |
92 |
91 |
114 |
105 |
116 |
( 30 |
81 ) |
10 |
75 |
133 |
165 |
123 |
83 |
( 19 |
61 ) |
20 |
88 |
99 |
124 |
109 |
85 |
( 28 |
54 ) |
30 |
85 |
102 |
127 |
108 |
90 |
( 28 |
58 ) |
50(1) |
40 |
110 |
137 |
54 |
97 |
( 31 |
61 ) |
CP |
61 |
52 |
65 |
39 |
1150 |
( 443 |
539 ) |
Note: all calculations were made without rounding off
RSG = Relative Suspension Growth; CE = Cloning Efficiency; RS = Relative Survival; RTG = Relative Total Growth; SC = Solvent Control = Ethanol; MMS = Methylmethanesulfonate; CP = Cyclophosphamide
(1)= 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol precipitated in the exposure medium
Table 2: Experiment 2; Cytotoxic and mutagenic response of 6,6’-di-tert-butyl-4,4’-butylidenedi-mcresol in the mouse lymphoma L5178Y test system
Dose |
RSG |
CE day2 |
RS day2 |
RTG |
Mutation frequency per 106survivors |
||
(μg/ml) |
(%) |
(%) |
(%) |
(%) |
Total |
( small |
Large ) |
Without metabolic activation |
|||||||
24 hours treatment |
|||||||
SC1 |
|
95 |
|
|
73 |
( 27 |
43 ) |
|
100 |
|
100 |
100 |
|
|
|
SC2 |
|
66 |
|
|
64 |
( 14 |
49 ) |
0.3 |
103 |
88 |
108 |
111 |
34 |
( 7 |
27 ) |
1 |
106 |
63 |
78 |
83 |
55 |
( 17 |
37 ) |
3 |
99 |
74 |
91 |
91 |
76 |
( 29 |
45 ) |
6.6 |
93 |
89 |
110 |
102 |
35 |
( 11 |
24 ) |
10 |
84 |
83 |
102 |
86 |
34 |
( 5 |
28 ) |
12.5 |
73 |
84 |
104 |
75 |
57 |
( 21 |
35 ) |
15 |
73 |
80 |
99 |
73 |
47 |
( 14 |
32 ) |
17.5 |
7 |
62 |
77 |
6 |
61 |
( 17 |
43 ) |
MMS |
125 |
52 |
65 |
80 |
751 |
( 343 |
335 ) |
With 12% (v/v) metabolic activation |
|||||||
3 hours treatment |
|||||||
SC1 |
|
97 |
|
|
200 |
( 97 |
84 ) |
|
100 |
|
100 |
100 |
|
|
|
SC2 |
|
101 |
|
|
138 |
( 71 |
58 ) |
1 |
100 |
94 |
95 |
95 |
131 |
( 68 |
55 ) |
3 |
106 |
105 |
107 |
113 |
124 |
( 70 |
46 ) |
10 |
108 |
94 |
95 |
103 |
130 |
( 66 |
56 ) |
30 |
73 |
110 |
111 |
81 |
123 |
( 51 |
64 ) |
50(1) |
47 |
123 |
125 |
59 |
100 |
( 32 |
63 ) |
60(1) |
44 |
90 |
91 |
40 |
108 |
( 40 |
64 ) |
65(1) |
26 |
102 |
104 |
27 |
126 |
( 55 |
63 ) |
70(1) |
16 |
104 |
105 |
17 |
128 |
( 52 |
68 ) |
CP |
61 |
61 |
62 |
38 |
1650 |
( 649 |
601 ) |
Note: all calculations were made without rounding off
RSG = Relative Suspension Growth; CE = Cloning Efficiency; RS = Relative Survival; RTG = Relative Total Growth; SC = Solvent Control = ethanol; MMS = Methylmethanesulfonate; CP = Cyclophosphamide
(1) = 6,6’-di-tert-butyl-4,4’-butylidenedi-m-cresol precipitated in the exposure medium
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
Additional information from genetic toxicity in vitro:
Both key studies, Chromosome Aberration and Gene Mutation, delivered the same negative result. Three supporting studies are also included for weight of evidence, again showing the same negative result.
Justification for selection of genetic toxicity endpoint
Endpoint conclusion determined from study utilising OECD & EU test guidance.
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.